A novel dendritic cell subset involved in tumor immunosurveillance.

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93

Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med (2009) 3.38

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 3.22

CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68

Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev (2010) 2.55

MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity (2014) 2.55

Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood (2009) 2.43

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 2.20

Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 2.17

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06

HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci U S A (2007) 1.85

CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med (2007) 1.82

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80

Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med (2007) 1.76

Natural killer-cell differentiation by myeloid progenitors. Blood (2010) 1.75

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74

PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood (2009) 1.74

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66

Following TRAIL's path in the immune system. Immunology (2009) 1.60

Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection. Blood (2008) 1.57

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood (2007) 1.52

Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med (2007) 1.49

Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res (2016) 1.45

Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell Int (2012) 1.44

The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol (2010) 1.43

T cell killing by tolerogenic dendritic cells protects mice from allergy. J Clin Invest (2011) 1.41

Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ (2007) 1.35

LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33

Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood (2007) 1.32

T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol (2008) 1.32

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica (2008) 1.27

CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol (2009) 1.23

Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol (2008) 1.19

Dendritic cell and NK cell reciprocal cross talk promotes gamma interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect Immun (2008) 1.15

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15

An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2007) 1.12

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09

Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med (2007) 1.04

Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. Oncoimmunology (2012) 1.04

Functional diversity of stem and progenitor cells with B-lymphopoietic potential. Immunol Rev (2010) 1.04

Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04

A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. Eur J Immunol (2011) 1.04

Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+ T cells. Proc Natl Acad Sci U S A (2011) 1.04

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology (2007) 1.03

Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection. PLoS One (2009) 1.02

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res (2009) 1.02

Viral-induced encephalitis initiates distinct and functional CD103+ CD11b+ brain dendritic cell populations within the olfactory bulb. Proc Natl Acad Sci U S A (2012) 1.02

Subversion of pulmonary dendritic cell function by paramyxovirus infections. J Immunol (2009) 1.02

CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest (2008) 1.01

Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response. Proc Natl Acad Sci U S A (2012) 1.01

Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin Exp Immunol (2008) 1.01

Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol (2012) 0.98

Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection. Infect Immun (2007) 0.94

The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases. Cell Mol Life Sci (2014) 0.93

Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol (2008) 0.93

Multiple hats for natural killers. Curr Opin Immunol (2010) 0.92

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology (2013) 0.91

Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90

Natural killer cells in non-hematopoietic malignancies. Front Immunol (2012) 0.89

IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res (2009) 0.89

Is it a DC, is it an NK? No, it's an IKDC. Nat Med (2006) 0.89

Novel immune modulators used in hematology: impact on NK cells. Front Immunol (2013) 0.89

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene (2014) 0.88

Anticancer effects of imatinib via immunostimulation. Nat Med (2011) 0.88

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. J Immunother (2009) 0.88

Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol (2010) 0.87

In vivo conversion of BM plasmacytoid DC into CD11b+ conventional DC during virus infection. Eur J Immunol (2008) 0.87

NFATc1 mediates Toll-like receptor-independent innate immune responses during Trypanosoma cruzi infection. PLoS Pathog (2009) 0.86

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology (2013) 0.86

MDC1 cleavage by caspase-3: a novel mechanism for inactivating the DNA damage response during apoptosis. Cancer Res (2010) 0.86

Characterization of early gamma interferon (IFN-gamma) expression during murine listeriosis: identification of NK1.1+ CD11c+ cells as the primary IFN-gamma-expressing cells. Infect Immun (2006) 0.85

The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84

Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). Int J Clin Exp Pathol (2014) 0.84

Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. J Autoimmun (2011) 0.83

Cytotoxic dendritic cells generated from cancer patients. J Immunol (2011) 0.83

Innate IFN-γ-producing cells in the spleen of mice early after Listeria monocytogenes infection: importance of microenvironment of the cells involved in the production of innate IFN-γ. Front Immunol (2011) 0.83

Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol (2013) 0.82

Immunological off-target effects of imatinib. Nat Rev Clin Oncol (2016) 0.81

Cutting edge: genetic characterization of IFN-producing killer dendritic cells. J Immunol (2009) 0.80

In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun (2009) 0.80

Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells. Front Immunol (2013) 0.79

Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus. J Immunol (2015) 0.78

Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal (2011) 0.78

Circulating HLA-DR(+) natural killer cells have potent lytic ability and weak antigen-presenting cell function. Hum Immunol (2008) 0.78

CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett (2015) 0.77

Depletion of B220(+)NK1.1(+) cells enhances the rejection of established melanoma by tumor-specific CD4(+) T cells. Oncoimmunology (2015) 0.77

The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells. Cancer Immun (2008) 0.77

A role for pre-mNK cells in tumor progression. J Immunother Cancer (2016) 0.77

Isolation of mouse lung dendritic cells. J Vis Exp (2011) 0.77

Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. Front Immunol (2016) 0.77

Dendritic cells in human Pneumovirus and Metapneumovirus infections. Viruses (2013) 0.76

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α -Galactosylceramide-Stimulated Natural Killer T Cells. Biomed Res Int (2013) 0.76

Cutting Edge: Induction of Inflammatory Disease by Adoptive Transfer of an Atypical NK Cell Subset. J Immunol (2015) 0.76

Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. J Immune Based Ther Vaccines (2008) 0.75

Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75

Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep (2017) 0.75

Modeling leukocyte-leukocyte non-contact interactions in a lymph node. PLoS One (2013) 0.75

Early Differentiation of Human CD11c(+)NK Cells with γδ T Cell Activation Properties Is Promoted by Dialyzable Leukocyte Extracts. J Immunol Res (2016) 0.75

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) 13.29

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Functions of natural killer cells. Nat Immunol (2008) 9.88

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02

Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol (2013) 7.94

Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03

Exosomes--vesicular carriers for intercellular communication. Curr Opin Cell Biol (2009) 6.96

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Exosomal-like vesicles are present in human blood plasma. Int Immunol (2005) 6.04

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87

TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86

Exosomes: a common pathway for a specialized function. J Biochem (2006) 5.79

Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78

Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol (2004) 5.71

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48

Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44

NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Cells release prions in association with exosomes. Proc Natl Acad Sci U S A (2004) 5.17

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell (2003) 4.94

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90

Viral hepatitis B. Lancet (2003) 4.86

Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol (2008) 4.78

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

The biogenesis and functions of exosomes. Traffic (2002) 4.49

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39

Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med (2003) 4.39

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32